AAI Acquires CAC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAI Acquires CAC


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Wilmington, NC (Oct. 26)—AAIPharma Inc. (www.aaipharma.com) completed its acquisition of contract research organization Cvitkovic & Associes Consultants S.A. (CAC, Le Kremlin Bicetre, France). CAC, which specializes in oncology drug development and medical consulting, will form the foundation of AAIOncology, a global business unit dedicated to developing cancer-fighting drugs.

According to Vito Mangiardi, AAI’s president of North American operations, “The experience and expertise brought by our new colleagues in the area of … oncology will significantly strengthen our company’s ability to execute large and global late-stage clinical development programs.”

The acquisition was made possible through a rights offering to existing shareholders and option holders that raised $30 million. The offering was backstopped by a group of principal shareholders led by JPMorgan.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here